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Abstract 
There are numerous commercial bioprinters based on the most prevalent bioprinting method 
of extrusion.  Despite the popularity of these bioprinters, other technologies like droplet-
based or drop-on-demand systems are rapidly gaining traction.   These alternate methods 
exhibit advantages in terms of cost, reliability and adaptability to a broader spectrum of cell 
types.  This paper describes the development and validation of a cost-effective, droplet-based, 
microvalve assisted bioprinter. The mean and the coefficient of variation values are reported 
for cell numbers dispensed via three modes: manual pipetting (mode 1), bioprinting without 
the aid of a cell mixer (mode 2) and bioprinting with the aid of a cell mixer (mode 3).  
Consistent and reproducible results were obtained when cells were dispensed with a mixer 
maintaining the cells in a homogenous suspension.  The printer was assessed for positional 
accuracy, variability in cell numbers and post-print viability for a range of cell types.  This 
report demonstrates that it is feasible to custom design a cost effective, microvalve based 
printer to suit specific cell types for a range of tissue engineering applications.  
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1. Introduction 
In this study, an open-source 3D printer was adapted to create a microvalve-assisted 
bioprinter (MAB) that incorporated low-cost, readily available hardware, software and 
control elements, that was evaluated for various parameters. Biofabrication or bioprinting is 
an emerging, disruptive technology with a broad spectrum of applications in the field of 
tissue engineering, regenerative medicine and drug toxicology. In its simplest form, this 
technology involves the accurate and uniform dispensation of living cells suspended in a 
culture media, into cell culture dishes. In complex workflows, growth factors, multiple cell 
types, biocompatible bio inks, etc. are used to seed cells onto and into pre-fabricated tissue 
scaffolds, to produce complex in vitro tissues [1-5].  Progress in this field is being driven by 
an insatiable demand for transplantable tissues and organs; while the waiting list for organs 
grows each year, the numbers of donors and successful transplants show less dramatic 
changes [6]. There is also a need for alternatives to animal models in drug toxicology and 
cosmetic testing.  In general, bioprinting needs fall into two broad categories; requirement of 
complex tissues with either structural or functional value, like multi-layered skin or vascular 
grafts/bone grafts, and the requirement for tissue models as a testing ground for drugs, toxins, 
cosmetics etc. [7-8]. Many research studies have shown successful dispensation of cell types 
with therapeutic value, using different types of print heads, for example, inkjet, laser, syringe 
or microvalve [9-11]. With the aid of stem cells, this technology is being extended to the 
creation of more complex organs like brain, bone, trachea, vasculature of tissues, organ chips 
like lung-on-a-chip etc [7]. There are also a number of commercial printers available that 
allow the printing of complex cell/material assemblies [9], [12].  
Despite the rapid progress in bioprinting in recent years, there are numerous challenges [12] 
that should be addressed to harness the benefits of this technology more effectively. Various 
modes of bioprinting may stress cells in many ways, for example; shear stress in extrusion, 
resulting in loss of cell viability, reduced pluripotency or differentiation potential in stem 
cells, or uncontrolled differentiation into non-specific cell types. If the primary aim is cell 
dispensing, then, ideally, bioprinting should be achieved in a scaffold-free manner [10], [13].  
Scaffoldless bioprinting is useful in many applications, including high throughput generation 
of cell based models, micro-tissues or cell spheroids within culture plates. Such clusters of 
cells are self-forming and do not require scaffolds to hold their shape post printing. Aseptic 
techniques are crucial when working with cell cultures; hence it is necessary for all the 
surfaces and moving parts that are directly in contact with cells to be autoclavable or to be of 
cell-culture grade.  Cells tend to aggregate during the printing process and cause clogging of 
the extrusion head. Methods are needed to ensure that cells are constantly in suspension 
before and during bioprinting, to ensure uniform and highly accurate dispensation of cells. 
The deposition of cells should be a fast, controllable and highly reproducible process in order 
to prevent dehydration of cell droplets and subsequent loss of viability and impairment of cell 
functions. Printing processes should be amenable to automation, and high throughput 
dispensation.  Moreover, it should be cost-effective, to allow more researchers to access this 
technology to drive cell-based research. The challenges faced in bioprinting have been 
addressed in many ways by various reports [14-15].  Reid et al have reported using 
microextrusion [14], in which a low-cost 3D printer was modified and pulled glass 
microcapillary pipettes were successfully used to print human induced pluripotent stem cells 
(hiPSCs).  The modified printer and needle showed reduction in cell clogging and improved 
cell resolution and viability.  A nozzle-less method was adopted in another report that 
eliminated the entire concern of clogging and shear stress [16].  The authors demonstrated 
that this method could be used with a wide variety of cell like hepatocytes, cardiomyocytes 
and fibroblasts while retaining high cell viabilities. 
 
The quality of printed cells depends on the choice of printhead; information gleaned from 
multiple reviews of printheads has been collated in Table 1. After weighing the pros and cons 
of these methods and when viewed in terms of cost effectiveness and cell viability, 
microvalve based systems were considered the most promising for cell dispensing.  
Microvalve-based bioprinting is classified as drop-on-demand (DOD) printing, along with 
inkjet and laser-based bioprinting [3], [9], [17], [18]. In this method, in contrast to the 
continuous printing, droplets containing cells or other biomaterials are printed out in a 
controllable, precise manner. A standard microvalve printhead consists of a source for 
pneumatic pressure, plunger and a solenoid coil.  The solenoid coil works like a magnetically 
actuated micro pump; it consists of a chamber with inlet and outlet valves, a permanent 
magnet, a flexible membrane and a set of drive coils that provide a controlled magnetic field. 
By changing the electric current flow through the coil, the strength of the magnet can be 
changed.  This creates an attraction or repulsion movement between the permanent magnet 
and coils, and this delivers the actuation force necessary to move the plunger in an upward 
motion. The ascending motion of the plunger aids in the controlled opening of a dispensing 
nozzle. Multiple nozzles can be attached to the system, with each one having a specific 
process.  This printhead is able to accurately dispense specific volumes ranging from tens of 
nanolitres (nl) to several microliters (µl). Some of the touted advantages of this system 
compared to other methods are; high cell viability (> 86%) [18], uniform cell dispensation 
[19], and high throughput printing.  This report indicates that microvalves could potentially 
be used on other cell types that have therapeutic value. 
 
In this study, a cost-effective microvalve-assisted bioprinter (MAB) was designed and then 
it’s performance evaluated using an array of six different cell types.  All the cell types were 
chosen for their value in regenerative medicine, cancer studies and drug testing.  These cells 
were tested in a scaffold-free, bio-ink free mode by suspending them in appropriate culture 
media prior to dispensation. The post-print cell data reflects the effect of the dispensing 
method alone on cell numbers and viability. For all bioprinting applications, reliability and 
scalability are key requirements.  In this work, the bioprinter was designed to address key 
bioprinting challenges, like cell clogging, and post print variability in cell numbers, cell 
viability and recovery, followed by assessment of the performance and reliability of the MAB 
in high throughput applications.   
 
Table 1 - Comparison of available cell dispensing printheads  
Print 
head 
Advantages Disadvantages References 
Laser • No issues of biomaterial 
clogging and viscosity 
• High cell viability 
• High resolution, droplet 
diameter is 10 – 120 µm 
• High cost 
• Potential genetic damage 
to cells 
• Requirement for laser 
absorbing material 
[9],[17-18],[20-24] 
Inkjet • Affordable cost 
• Usage of multiple nozzles 
• Continuous or droplet 
dispensing capability 
• Moderate cell viability 
• Moderate to high 
resolution, droplet 
diameter is 50 – 300 µm 
• Adaptable to high-
throughput 
• Shear stress applied to 
cells 
• Adverse effects of high 
vibration frequencies 
and/or thermal effects 
• Nozzle clogging 
• Limited size of droplets 
[9],[17-18],[22-23] 
Valve • Most advantages similar to 
inkjet method 
• Low to moderate 
resolution,  droplet 
diameter is 10 µm – 1mm 
• Voltage controllable valve 
• Low shear stress 
• Uniform cell dispensation 
• Gentle on cells, high cell 
viability 
• Nozzle clogging 
• Droplet size is limited by 
nozzle size 
[9],[17-18],[23] 
 
 
 
2. Materials and Methods 
2.1 Machine Design 
The specifications for the MAB system are shown in Table 2, and the machine setup is shown 
in Figure 1.  The development of the system was focused on the driving mechanism, micro 
valve, mixing mechanism and syringe pump.  
Table 2 – The microvalve-assisted bioprinter (MAB) system specifications  
 
No. Specifications 
1 Dispense therapeutic cells with high viability 
2 Dispense cells in media with droplet volume of 100 µl – 110 µl 
3 Positioning accuracy to be more than 85% 
4 Dispense into a 96-well plate  
5 Have a deposition rate of less than 10 minutes per 96-well plate 
 
A RepRapPro Ormerod 2 3D Printer, originally intended for extruding different types of 
plastics, was modified to dispense droplets of culture media containing cells into a 96-well 
format cell culture dish (Figure 1). Only the X, Y and Z controls were used in this design. 
The extruder was replaced with a VHS Nanolitre Dispense Valve (Lee Products Ltd, 
INKX0514850A) with a Hex MINSTAC with Jewelled Orifice Dispensing Nozzle - 100 µm 
(Lee Products Ltd, INZA4650935K). A syringe pump was fabricated using a disposable glass 
syringe with a 10 ml Luer Lock tip (Thermo Fisher Scientific), a Nema 23 Stepper Motor, 
and  with 3D printed Acrylonitrile Butadiene Styrene  frame components constructed using a 
Makerbot 3D printer. A silicone tube of inner diameter 3.5 mm was used to connect the glass 
syringe to a 062 to 125/156 Minstac adaptor (Lee Products Ltd, TMDA9502950Z), which in 
turn connected to a PVC tube of inner diameter 1.05mm (Lee Products Ltd, 
TUVA4220900A) which led to the microvalve.  To maintain a homogenous suspension of 
cells during the printing process and to prevent cell clogging in the nozzle, a magnetic mixing 
system (ThermoFisher Scientific, 88880007) was added to the bioprinter module. 
Additionally, aluminium frames and wooden blocks were constructed to support the syringe 
pump above the magnetic stirring mechanism. Positioning jigs made of machined acrylic 
were used to position a 96 microwell plate in place for accurate dispensation.  
 
An Arduino Mega board was programmed and used to control the axis motor and syringe 
pump. The Arduino Mega sent signals to Easy Drivers that allowed the control of the speed 
and revolution of the motors. It also sent signals to the microvalve driver (Lee Products Ltd, 
IECX0501350A) to control the opening and closing mechanism of the valve. The microvalve 
required spike and hold voltages of 24 V and 3.5 V respectively, supplied by a step-up 
voltage regulator from Polulu for the former and the power supply for the latter. The 
bioprinter head was designed to move from home position to the initial start position before 
cell dispensation. It was programmed to sequentially dispense 100 µl into each well, row by 
row across the 12 rows of the 96-well plates. 
 
2.2 Positioning accuracy 
 
The positioning accuracy was assessed by programming a predetermined distance (referred to 
as the theoretical distance) for the print head to move based on revolutions of the rotor, and 
comparing this with the actual distance moved (referred to as the experimental distance), 
which was measured by a Vernier calliper. The measured distance was correlated to the 
number of revolutions turned.  This experiment was repeated in sets of 10 for 3 different 
revolutions of the motor, namely; 1, 2 and 3 revolutions. 
 
 2.3 Volumetric consistency tests 
The incremental weights of distilled water with a nominal volume of 100 µl dispensed either 
manually or using the bioprinter into a 96-well plate, were recorded. For the manual method, 
a 200 µl single channel pipette set to a volume of 100 µl, was used.  In the bioprinted method, 
nominal 100 µl volumes were dispensed from a 100 µm nozzle.  The recorded weights data 
were then converted to an average droplet volume (in µl) by dividing the total mass of 
dispensed droplets (g) by the number of dispensed droplets. 
 
 2.4 Cell Culture 
All cell types used in this experiment were cultured in a laboratory incubator at 37.0oC (± 
0.5oC) and 5.0% CO2 (± 0.5%). All cell types were thawed, subcultured, maintained and 
cryopreserved as per each manufacturer’s instructions. Cells were passaged every 2 to 3 days 
with 0.025% trypsin/ethylene diamin tetraacetate (EDTA; PAN Biotech P10-029100) and 
cells were harvested in the log phase of cell growth for bioprinting experiments. The 
complete media for each cell type was filtered in 0.2 µm filter, aliquoted into 50-ml tubes and 
stored at 4°C.  The details for each cell type are shown in Table 3.  
Table 3 – Cell culture specifications 
 
Cell cultures Basal cell culture media Culture supplements 
Human Colorectal Cancer 
cell lines (HCT116) 
(ATCC® CCL247™) 
DMEM or Dulbecco’s Modified Eagle’s medium /High 
Glucose (GE Healthcare Life Sciences SH30022.01) 
Each 500- ml bottle of basal media was supplemented with 10% FBS or fetal 
bovine serum (v/v), triple 0.1 µm sterile filtered and heat inactivated (Serana 
Australia S-FBS-AU-015)  0.1mM MEM NEA or minimum essential medium 
nonessential amino acids (PAN Biotech P08-32100), 2mM L-Glutamine 
(HyClone® SH30034.01), 100 UmL−1 penicillin/streptomycin (HyClone® 
SV30010) 
Mouse Embryonic Stem 
cells (mESCs) from strain 
C57BL/6 mouse 
blastocyst 
(ATCC® SCRC1002™) 
DMEM/High Glucose (GE Healthcare Life Sciences 
SH30022.01). Mouse Embryonic Stem cells (mESCs) were 
cultured on 35 mm dishes that were pre-coated with 0.1% 
gelatin dissolved in ultrapure water (Merck Millipore ES-
006-B).  After every passage, cells were seeded onto 0.1% 
gelatin-coated Petri dishes. 
Each 500- ml bottle of basal media was supplemented with 15% of FBS, triple 0.1 
µm sterile filtered and heat inactivated (Serana Australia S-FBS-AU-015),  
0.1mM MEM NEA (PAN Biotech P08-32100), 2mM L-Glutamine (HyClone® 
SH30034.01), 1mM sodium pyruvate (Gibco® by Life Technologies 11360-070), 
100 UmL−1 penicillin/streptomycin (HyClone® SV30010), 1000 UmL−1 
leukemia inhibitory factor (LIF: ESGRO, ESG1106) and 0.1mM β-
mercaptoethanol (Sigma Aldrich,  M3148) 
Primary Normal Human 
Dermal Fibroblast Adult 
Cells (HDFa cells, 
C0135C) 
Medium 106 (M106500) supplemented with the Low 
Serum Growth Supplement Kit (LSGS, S003K) prior to use 
(all supplied by ThermoFisher Scientific) 
Each 500- ml bottle of basal media was supplemented with LSGS kit which has 
2% FBS v/v, hydrocortisone 1 µg/ml, hEGF or human epidermal growth factor 10 
ng/ml, hFGF or human fibroblast growth factor 3 ng/ml and heparin, 10 µg/ml. 
Primary Normal Human 
Epidermal Keratinocyte 
cells (NHEKa cells, C-
12003) 
Keratinocyte growth medium 2 (C20211) which is a serum-
free medium that is supplemented with Keratinocyte growth 
medium 2 kit (C20111, all supplied by Promocell).   
Each 500-ml bottle of basal media was supplemented with BPE or bovine 
pituitary extract 0.004 ml/ml, hEGF (recombinant human) 0.125 ng / ml, insulin 
(recombinant human) 5 μg / ml, hydrocortisone 0.33 μg / ml, epinephrine 0.39 μg 
/ ml, transferrin, (human) 10 μg / ml and CaCl2 0.06 mM.  
 
Human bone-marrow 
derived Mesenchymal 
Stem Cells (hMSC, 
ATCC® PCS-500-041™) 
DMEM/High Glucose (GE Healthcare Life Sciences 
SH30022.01) 
Each 500- ml bottle of basal media was supplemented with 10% of FBS (v/v), 
triple 0.1 µm sterile filtered and heat inactivated (Serana Australia, S-FBS-AU-
015), 0.1mM MEM NEA (PAN Biotech P08-32100), 2mM L-Glutamine 
(HyClone® SH30034.01), and 100 UmL−1 penicillin/streptomycin (HyClone® 
SV30010). 
Human umbilical vein 
endothelial cells 
(HUVEC cells, CC-2517, 
single donor) 
Endothelial Basal Medium-2 (EBM™-2, CC-3156) 
supplemented of with EGM™-2 SingleQuots™ (CC-3162, 
all supplied by Lonza). 
Each 500- ml bottle of basal media was supplemented with hEGF, 0.5 ml, VEGF 
or vascular endothelial growth factor, 0.5 ml, R3-IGF-1 or recombinant analog of 
human insulin-like growth factor, 0.5 ml, ascorbic acid, 0.5 ml, hydrocortisone, 
0.2 ml, hFGF-β, 2.0 ml, heparin 0.5 ml, FBS, 10.0 ml, and GA or 
Gentamicin/Amphotericin-B, 0.5 ml. 
 
 
  
2.5 Cell viability and cell recovery assays 
All culture experiments were repeated three times to ensure consistency and reproducibility. 
During routine cell passaging and to quantify the viable cell numbers in cell suspensions prior 
to dispensation, cells were treated with 0.4% Trypan blue stain solution (Gibco, 15250-061) 
to evaluate cell viability via the exclusion dye test method. Viable cell numbers were 
determined manually using a hemoctyometer counting device (Heinz Herenz, 1080305). For 
quantitative assessment of viable cells that were recovered after high throughput dispensation 
by manual pipetting or by bioprinting, CellTiter-Blue® Cell Viability Assay from Promega 
(G8081) was used as per manufacturer’s instructions. In general, 20 μl of resazurin reagent 
was aliquoted into each 100 μl of medium containing cells in a 96-well format.  Fluorescence 
values for cell samples were detected using filter sets; 560nm for excitation and 590nm for 
fluorescence emission using Tecan plate reader (Tecan Trading AG Infinite® 200 PRO 
NanoQuant Plate Reader).  The post-print viable cell numbers were compared with viable cell 
numbers prior to dispensation and are reported here as average cells recovered per well, and 
as variations in cell numbers across all the 96 wells in a single plate or COV.  
 
For visual, qualitative assessment of both live and dead cells, cells were stained with Calcein 
AM (Cayman Chemical Company 14948) which is a non-fluorescent, hydrophobic 
compound that can permeate living cells. 2mM stock solution was used at a final 
concentration of 1 µm. Propidium iodide (PI) is a red fluorescent stain that cannot permeate 
living cells. Stock concentration of 1.5 mM of PI was diluted to 2 μM working solution 
before staining of all cell types.  Post-staining, cells were incubated in the dark for 15 – 20 
mins.  Fluorescence intensity was recorded using a 490-nm excitation filter and a 520-
emission filter for the calcein stain, and an excitation maximum of 535 nm and an emission 
maximum of 617 nm for the PI stain. Cell images were captured and recorded using an 
Olympus inverted fluorescent microscope system (1XT3).  Three random fields were checked 
for each sample.  Calcein AM and PI stains were used to generate live/dead fluorescent cell 
images for all the cell types that were dispensed either by manual pipetting or by bioprinting 
methods.  
 
 
2.6 Standard curves and cell dispensation modes 
To generate standard curves for each cell type, viable cell numbers for each cell type was 
determined using 0.4% Trypan blue stain solution and manual counting of unstained cells, 
prior to dispensation.  Then viable cell suspensions of nominal numbers of 105 cells/ml were 
dispensed into 96-well plates using 3 different increment values; 2µl, 5µl and 10µl per row.  
After addition of resazurin, plates were incubated and readings were recorded at 4 hours post-
incubation, using the Tecan plate reader, and standard curves generated from the data.  
 
Cell samples were dispensed via three modes, namely manual (mode 1), bioprinting without 
mixer (mode 2) and bioprinting with mixer (mode 3). In the mode 1, a 100 µl volume of 
viable cell suspensions of nominal numbers of 105 cells/ml were dispensed into 96-well 
plates, using a 200 µl single channel micropipette.  Single channel was used instead of 
multichannel, in order to obtain data that is comparable with well-to-well dispensation from a 
single print head in the bioprinter.  In the modes 2 and 3, cell dispensation was done using the 
same volume and cell numbers as in mode 1, with the aid of a 100 µm nozzle and either with 
or without a mixer attached to the main body of the bioprinter, respectively.   
 
Then, for each cell type and dispensing method cells were separately dispensed onto 96-well 
plates.  After addition of resazurin and incubation for 4 hours, fluorescence data was recorded 
and cell concentrations estimated using the corresponding standard curve.  The coefficient of 
variation (COV) was calculated from; CV =   σ
µ
  
where σ is the standard deviation of the spread of data, and µ is the mean of the spread of 
data [25]. 
 
2.7 Statistical analysis 
All cell culture experiments were conducted as triplicates to ensure consistency and 
reproducibility, as highlighted in previous section.  All data were presented as mean ± 
standard deviation. The statistical significance of experimental data was determined by two-
way analysis of variance (ANOVA) [26] to compare values derived for manual and 
bioprinted methods for each cell type.  The paired wise test was evaluated using the Tukey 
post-hoc test at the significance level of less than 0.05 (p <0.05) available in Graphpad Prism 
software (version 7.04).  Box and whisker plots were obtained for the data generated for all 
cell types. In the graphical display of the results for each repeat, the error bar indicates the 
variability of the mean value over 96 wells in a single plate. 
 
3. Results 
 
3.1 Machine positional accuracy 
The positional accuracy was greater than 98% in the X and Y axes, respectively and ranges 
from 81.33% to 89.50% in the Z axis.  In Table 4, the averages of each set of 10 for three 
different rotor revolutions (1-3) are shown for X, Y and Z axes.   
 
Table 4 – Accuracy testing of the three axes (X, Y and Z) 
 
X-axis 
(number of 
revolutions 
Average theoretical distance 
(mm) 
Average experimental distance 
(mm) 
Percentage 
accuracy (%) 
1 37.70 37.20 98.67 
2 75.40 74.59 98.93 
3 113.10 111.29 98.40 
Y-axis 
(number of 
revolutions 
Average theoretical distance 
(mm) 
Average experimental distance 
(mm) 
Percentage 
accuracy (%) 
1 37.70 37.37 99.12 
2 75.40 75.22 99.76 
3 113.10 111.94 98.97 
Z-axis 
(number of 
revolutions 
Average theoretical distance 
(mm) 
Average experimental distance 
(mm) 
Percentage 
accuracy (%) 
1 1 0.87 87.00 
2 2 1.79 89.50 
3 3 2.44 81.33 
 
3.2. Dispensed volume repeatability 
The average volume of nominal 100 µl aliquots of distilled water dispensed into the three 96-
well plates was calculated to be 142 µl for the manual method as compared to the average 
volume of 115.2 µl for the bioprinter assisted method, as in Figure 2. The calculated 
percentage errors of 42% and 15.2% were obtained for manual and bioprinted methods, 
respectively. COV values for both methods were calculated, with an average of 0.139 versus 
0.089 for the manual and bioprinted methods, respectively.  
  
3.3 Bioprinter evaluation with HCT116 cells  
The overall design of the bioprinter, complete with 100 µm nozzle and mixer module was 
tested by comparing cell counts of HCT116 cell samples dispensed via three modes, namely 
manual (mode 1), bioprinting without mixer (mode 2) and bioprinting with mixer (mode 3). 
Negative control consisted of HCT116 cells treated with 30% hydrogen peroxide which 
causes cell death by oxidative stress. The actual numbers of total cells dispensed in each 
method cannot be gauged accurately, so the evaluation of bioprinter and printing modes was 
done by comparing post-print, recovered, viable cell numbers with the values prior to 
dispensation. Approximately, 100 µl of bio-ink (cells suspended in culture media) was 
dispensed into each well of a 96-well plate and the average numbers of viable cells recovered 
from each method was estimated to be 159 cells/well for the negative control, 447 cells/well 
for mode 1 and 635 cells/well and 720 cells/well for the modes 2 and 3, respectively (Figure 
3).   
 
Additionally, variation in dispensed cell numbers for the three modes was estimated after 
dispensation of a 100 µl volume of culture media (containing nominally 105 cells/ml), into 
each well of a 96-well plate. Data sets were analysed for average cell counts post-printing and 
variation in cell numbers across the 96-well plate, using two-way ANOVA. Results show a 
significant difference (p < 0.0001) in cell counts or cells/well when mode 1 was compared 
with the other two modes (Figure 4, panel A). Average cell numbers post-printing ranged 
from 730 - 1070 cells/well for each repeat (sets 1-3) of mode 1.  Whereas, average cells 
numbers for mode 2 was higher and ranged from 1230 – 1320 cells/well and for mode 3 it 
was highest at 1370 – 1500 cells/well.  Data distribution was evaluated using box and 
whisker plots as shown in Figure 4, panel A.  Box plots for sets 1-3 on mode 1 show longer 
upper and lower whisker and a wider spread of cell numbers, as compared to modes 2 and 3.  
In each set, mode 3 shows a tighter distribution of cell numbers, with a majority of data 
points lying closer to the median values. 
 
With regards to the COV or the cell count relative to the mean (Figure 4, panel B), for each 
set, the COV is lower for cells dispensed by mode 3 with an average value of 8.54, as 
compared to mode 1 and mode 2 with average values of 30.1 and 16.5, respectively.  Figure 
4, panel C shows the comparison of average COVs for sets 1-3 dispensed via the three 
modes.  COV of mode 3 is significantly different from that of mode 1, as indicated by the p 
value (p < 0.000) 
  
3.4 Bioprinting of different therapeutic cell types 
MAB cell dispensation (nominal volume of 100 µl of culture media with cells) using only 
mode 1 and mode 3 was evaluated for five different cell types: mouse embryonic stem cells 
(mESC), human mesenchymal stem cells (hMSC), adult human dermal fibroblasts (HDFa), 
adult normal human epidermal keratinocytes (NHEKa) and human umbilical vein endothelial 
cells (HUVEC). Figure 5, panels A - E shows the comparison of cell counts between manual 
and bioprinted method for every cell type. Apart from a few cases, for instance, set 2 of MSC 
(p value > 0.999), the majority show a significant difference in cell counts or cells/well for 
the two methods.  
 
Figure 6, panel A is an overview of cell count distribution of set 3 for all cell types.  All cell 
types show a tighter distribution of cell numbers for mode 3 as compared to mode 1.  Figure 
6, panel B shows the comparison of COV values between mode 1 and 3 for each cell type. 
With the exception of HDFa cells, all the others showed a substantial decrease in variability 
of cell numbers for the bioprinted samples.   
 
3.5 Live/dead cell assessment of printed cells 
Figure 7 is a live/dead cell assay for all six cell types tested.  It shows cell images taken after 
manual and bioprinted modes of cell dispensation using the magnetic mixer and 100 µm size 
nozzle for all the cell types.  Calcein AM and propidium iodide reagents were used to 
indicate live/dead cells as green or red colored cells, respectively. In each case, as shown 
pictorially, the live/dead cells were comparable between manual and bioprinted modes, 
indicating that there were no visible adverse effects on bioprinted cells. 
 
4. Discussion 
The major design aspects of the MAB described in this paper include; a standard open-source 
microvalve printhead, a syringe pump, magnetic agitator or mixer, XYZ stage and an 
electronics board.  These modifications were specifically incorporated into the system, with a 
focus on some key issues in bioprinting like cell clogging, cell viability, repeatability and 
consistency in cell numbers post-printing. The printhead was provided with a hold voltage of 
3.5 V and a spike voltage of 24 V to avoid damaging the solenoid coil and the printed 
samples. A syringe pump was used to provide a positive pressure of 8 psi to the plunger 
within the printhead.  A nozzle diameter of 100 µm was used to dispense six different cell 
types ranging from 10 µm – 30 µm in cell diameter. The nozzle was directly mounted onto 
the microvalve to reduce the overall size of the valve.  This caused a reduction in the time 
taken for the cell suspension to travel from the microvalve until it exits the nozzle.  In spite of 
the multiple advantages of microvalve printing method, the limited range of nozzle size 
available posed a challenge: cell clogging.  This was solved by attaching a magnetic mixer to 
the syringe pump to keep cells in uniform suspension before and during the printing process. 
The mixer aided significantly in maintaining the homogeneity of cell suspensions which in 
turn prevented a build-up of cells at the nozzle’s orifice and allowed for a sequential printing 
into multiple 96-well plates. 
 
The bio printer’s design features allowed for all of the system specifications (as listed in 
Table 2) to be met.  Positional accuracy of all three axes was estimated to be quite high (98% 
for X and Y axes, and up to 89.5% for the Z axis in Table 4). The reason for the poorer 
accuracy in the z axis is not clear, but we assume that this axis of the RepRap printer was 
poorly calibrated. However, the errors were repeatable and so once a program had been 
developed which worked for a 96 wellplate, the program could be executed consistently. The 
printer was able to accurately dispense 100 - 110 µl volumes of liquid into each well of a 96-
well plate with high accuracy and very low percentage error (15.2%) and COV values (0.089) 
as compared to manual dispensation (42% and 0.139, respectively) (Figure 2).  The 
dispensation rate was approximately 4.5 minutes for one 96-well plate. When the 100 µm 
nozzle in conjunction with the mixer (mode 3) was used to dispense culture media containing 
HCT116 cells into 96-well plates, cell recovery values were found to be the highest, with an 
average of 720 cells/well, as compared to dispensation via manual or mixer-free methods 
(447 and 635 cells/well, respectively; Figure 3). Mode 3 also showed uniform dispensation of 
cells across all the wells of the culture plate, for all three repeats of the experiment. Average 
cell counts for Mode 3 were the highest at 1370 – 1500 cells/well (Figure 4, panel A) and 
closest to the value of the initial cell sample used for dispensation (1000 – 1500 cells/well).  
Moreover, when data for cell counts were analysed and compared by two-way ANOVA, box 
and whisker plots and COV values, it was seen that there is significantly less variation in cell 
dispensation (p<0.0001), with a majority of data points clustering near the median, and the 
lowest COV of 8.54 for mode 3.  The results were reproducible and consistent across all three 
repeats, sets 1-3, for HCT116 cells (Figure 4).  
 
The bioprinter was further evaluated using five other cell types.  Mouse embryonic stem cells 
(mESC) mirrored all the results seen with HCT116 cells, in terms of cell recovery, uniform 
cell dispensation etc.  For all the other cell types too, consistency in cell deposition and low 
variation was evident (Figures 5 and 6).  However, there were a few differences in some of 
the printing parameters; cell recovery values were lower for mode 3 in a few sets (sets 2 and 
3 in HDFa), COV was not significantly lower for mode 3 in HDFa cells. Also, for hMSC, 
NHEKa and HUVEC cells, at least one of the three sets did not show significant difference 
between manual and bioprinted modes (Figure 5).  These differences in printing are 
considered to be caused by differences in sizes between the tested cell types. Approximate 
values for cell diameter are; HDFa/NHEKa – 25 to 30 µm, MSC/HUVEC – 15 to 16 µm, 
HCT116/mESC – 10 to 12 µm. It is worth noting that changes of ~20% in cell diameter will 
result in changes of ~50% in cell volume, which are likely to significantly change the 
behaviour of the bio-ink both in the agitator and in the microvalve. The results suggest that 
different cell types would need to have their cell concentrations and agitation conditions 
optimised for maximum yield of deposited cells for a given nozzle size. 
 
Post-printing, live and dead cell assessment was evaluated with the aid of calcein and PI 
stains (Figure 7). The results showed that cell mixing using the magnetic mixer and 
dispensation via the solenoid valve did not impose any discernible deleterious effects on the 
tested cells.  Overall, the design features of this MAB provided many benefits that 
outweighed some of the inconsistencies seen in the printing of different cell types.  As all the 
hardware parts and controls were either sourced from various online vendors or 3D printed 
and the software program was developed in-house, the overall costs were in the range of 
$3000 - $4000. The results do show that there is no one-size-fits all design of a bioprinter, 
and that there is a need to further adapt the MAB to suit specific cell types or applications.   
 
Microvalves are increasingly being employed to print biological materials for many research 
applications.  A commercial version called The Biofactory (regenHu Ltd., Switzerland) was 
shown to be capable of lung tissue engineering [27].  It was used to achieve layer-by-layer 
bioprinting of a human air-blood tissue barrier analogue made of endothelial and epithelial 
cells and a basement membrane. These types of artificial lung models have applications in 
drug testing and in regulatory toxicology studies [27].  Under non-commercial printers, one 
example is the printer developed by Faulkner-Jones et al [19], [28]. It is the first study that 
analysed the effect of microvalve printing process on the cell viability and pluripotency of 
human stem cells (hESCs).  Microvalve printing of embryoid bodies (EBs), using hESC, 
resulted in dramatically smaller size variations when compared with EBs produced manually.  
Their results indicate that their printer has high spatial accuracy, high speed (40 droplets per 
second), and high cell viability. The same research group have also successfully used this 
printing method to generate hepatocyte-like cells from human pluripotent stem cells [28]. It 
was again demonstrated that the process did not affect the pluripotency of the stem cells and 
the downstream differentiation process leading to hepatocyte-like cells. Lee et al have shown 
the biofabrication of fibroblasts containing hydrogel scaffolds with microfluidic channels, 
which is meant to mimic in vivo tissues [29].  Most of these reports show the usage of an 
array of different cell types of therapeutic value. Additionally, a host of biomaterials are 
being co-printed along with these cell types [17]. Reagents like alginate, collagen, fibrin, 
polyetheline glycol, gelatin, biopolymers etc. are routinely used either as bioinks or as 
scaffolds to support cells during the printing process.  Other materials like DNA, drugs, 
hormones and growth factors are also making their way in biofabrication [30], [31]. This 
indicates that any custom-designed printer would be required to cater to innumerable printing 
needs and research applications.   
 
While it is not possible to design a universal printer to meet all these demands, we have 
shown that it is feasible to design a printer that can fulfil at least a subset of these needs.  
Each of the cells tested on our printer has been shown to have therapeutic value in research or 
regenerative medicine and we have demonstrated that they can be printed with reliable 
consistency and cell viability.  Keratinocytes and fibroblasts are regularly used by research 
groups that generate in vitro skin either for transplantation or for drug testing [32], [33], [34].  
Mouse embryonic stem cells and mesenchymal stem cells are used in differentiation studies 
to generate a range of cell types like cardiomyocytes, neural stem cells etc [35], [36].  
Endothelial cells are vital for generation of vasculature in bioprinted tissues and organs, as 
they are capable of in vitro angiogenesis [37].  Microvalves do not show a high resolution as 
compared to inkjet method; ~150 µm vs ~20 µm [18], but the larger volumes deposited are 
more suited to co-printing multiple biomaterials like cells, specific genes, hydrogels like 
collagen and alginate, growth factors etc, which requires a bigger nozzle size.  Hence there is 
a trade-off between reduced printing resolutions versus printer productivity and versatility.  
Future design aspects would require considering the evolving needs of the medical and 
clinical research industry. 
 
The MAB printer will be further developed to extend its applications in tissue engineering 
and drug/cosmetic toxicology testing.  For example, since the European Commission’s 
issuance of a complete ban on all animal-tested cosmetics and their ingredients, they have 
been urging their trading partners to follow suit.  This has led to a scramble for alternatives to 
animal testing by a majority of the cosmetic industries.  Some proposed solutions include 
artificial skin constructs for the testing of topical creams. Bioprinters can be used to automate 
the process of creating homogenous skin sheets to serve as a testing ground for cosmetic 
ingredients.  Another application is in drug toxicology testing and in personalized medicine.  
Using microvalve bioprinters, human embryonic stem cells can be printed out as droplets of 
highly uniform cell spheroids or embryoid bodies (EBs) that mimic the developmental 
processes of embryogenesis.  These spheroids consist of ectoderm, mesoderm and endoderm 
and are representative of all three germ layers of a growing embryo.  These EBs have 
multiple applications; differentiation into different tissue types (cardiac cells, hepatocytes 
etc.) which can be used in tissue transplantation, development of personalized medicines and 
embryotoxicity testing.  We conclude that this method of cell printing has potential to serve 
as a platform for a broad array of tissue engineering applications. 
 
5. Conclusion 
 
The fully developed and assembled MAB system (Figure 1) was validated for various 
parameters; accuracy of the three axes, volumetric validation, and evaluation of magnetic 
mixer and nozzle sizes, consistency in printed cell numbers, and cell viability post-printing. 
The MAB was also tested for its ability to support printing of cells that can be broadly 
categorized into three cell types; cancer cells, stem cells and primary cells.  All cell types 
were resuspended in appropriate culture media and were printed in scaffold-free and bio-ink 
free conditions. Most of the results show that the MAB along with the modifications is able 
to successfully print a wide range of cell types. There were many major benefits noted in the 
final design of the system; cost effectiveness, high cell recovery, uniform cell dispensation, 
lack of cell clogging, capability to print multiple cell types, and high-throughput capability. 
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Figure 1. Schematic diagram of the Microvalve-based bioprinter or MAB:  Component parts are labelled from A –
H.  The arrows on F indicate the direction of sample flow from B to G.  Nozzle of 100 µm size (H) was  attached 
to G for testing
Figure 2.  Volumetric validation of the MAB: Average volumes (in µl) of 
distilled water dispensed into 96-well plates by manual and bioprinter assisted 
methods are represented graphically.  
Figure 3. HCT116 cells were printed manually or by using 100 µm nozzle, with or without mixer. About 100 µl volume of culture media
containing cells were dispensed into each well. Panel A shows the comparison of average numbers of recovered cells from a 96-well plate,
post-dispensation, by different methods. Negative control values are for cells dispensed after treatment with 30% hydrogen peroxide. Panel B
shows the corresponding standard curve that was used to calculate cell numbers. Readings at 4 hours gave a better R2 value of 0.9602 than the
24 hour time point.
A B
Figure 4: Panels A – B show the comparison of data sets for HCT116 cells,
by two-way ANOVA analysis and box and whisker plots (A) and COV values
(B). Cell counts were determined post-printing using three modes 1 – 3 as
indicated in the figure. Data generated in three experimental repeats are
shown as Set 1 – 3. In Panel B, the average COV values for all three sets are
shown.
A B
A B C
Figure 5: Panels A – E show the comparison of data sets for five different
therapeutic cell types as indicated, using two-way ANOVA analyses. Cell
counts for 96-well plates were determined post-printing, using two - modes 1
and 3, as indicated in the graph’s key. Data generated from three experimental
repeats are shown as Set 1 – 3.
Mode 3 - Bioprinted with mixer
Mode 1 - Manual
D E
Figure 6: Panels A – B show the comparison of data sets for six different
therapeutic cell types as indicated, using box and whisker plots (A) and COV
values (B). Cell counts were determined post-printing using two modes 1 and
3, as indicated in the graph’s key. Data generated from three experimental
repeats are shown as Set 1 – 3.
BA
Figure 7. Live/Dead cell assay: Six cell types were evaluated for viability after printing by manual and bioprinted methods (100 µm with
mixer). Calcein and Propidium Iodide (PI) stains were used to stain the cells green (live) and red (dead). Fluorescence intensity of cells was
recorded using 490 nm excitation filter and a 520 emission filter for calcein and excitation maximum of 535 nm and an emission maximum of
617 nm for PI stain. The size of the scale bar for all the cell images is 100 µm.
